Skip to content

Analysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy

Analysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy for the Follow-up of Patients With Transthyretin Amyloidosis Treated With Tafamidis

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04849754
Acronym
QUANTI-SUV
Enrollment
30
Registered
2021-04-19
Start date
2021-02-25
Completion date
2025-12-31
Last updated
2024-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Amyloidosis

Brief summary

Recently, treatment with tafamidis in patients with cardiac ATTR lead to a significant reduction in mortality. The Perugini score is commonly used on planar bone scans to differentiate cardiac ATTR from other amyloidosis or normal patients but fails to evaluate amyloid burden and patient prognosis. Although semi-quantitative methods have been suggested to evaluate the amyloid burden, there a need for quantitative methods for longitudinal assessment of the disease.

Detailed description

Cardiac amyloidosis is a cause of restrictive cardiomyopathy with preserved ejection fraction associated with amyloid fibrils deposits in the myocardium. Two types of amyloid commonly infiltrate the heart: immunoglobulin light-chain amyloid (AL), and transthyretin-related amyloid amyloidosis (ATTR). Cardiac imaging is currently used for the diagnosis of ATTR, including planar scintigraphy with bone seeking radiopharmaceuticals, cardiac magnetic resonance and echocardiography with global longitudinal strain assessment.Although semi-quantitative methods have been suggested to evaluate the amyloid burden, there a need for quantitative methods for longitudinal assessment of the disease.

Interventions

DIAGNOSTIC_TESTbone scintigraphy

Bone scintigraphy

Sponsors

GCS Ramsay Santé pour l'Enseignement et la Recherche
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient, male or female, over 18 years of age * Patient diagnosed with transthyretin cardiac amyloidosis confirmed by scintigraphy * Patient with signed consent

Exclusion criteria

* Patients with systemic AL amyloidosis * Protected patient : major under guardianship, tutorship or other legal protection, deprived of liberty by judicial or administrative decision * Pregnant or breastfeeding woman

Design outcomes

Primary

MeasureTime frame
Measurement of SUVmax by quantitative analysis by bisphosphonate scintigraphy6 months

Countries

France

Contacts

Primary ContactFrederic MOUQUET
fmouquet@ovh.fr0642377375

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026